| Professional Services Industry | Industrials Sector | - CEO | TWSE Exchange | TW0006847007 ISIN |
| Taiwan Country | 42 Employees | - Last Dividend | - Last Split | - IPO Date |
Puriblood Medical Co., Ltd. is a Taiwan-based company focused on developing and commercializing advanced blood cell separation products. Since its inception in 2016, Puriblood has dedicated itself to providing innovative solutions aimed at enhancing the safety and efficiency of blood transfusions and related medical procedures. Located in Hsinchu, Taiwan, the company leverages cutting-edge research and development to create products that meet the critical needs of healthcare providers and patients alike. Central to their innovation is the development of P-Tex Technology, a novel approach to blood filtration that uses a zwitterionic copolymer structure inspired by biological mechanisms.
Puriblood offers a range of leukocyte reduction filters designed for red blood cells, platelets, and whole blood. These products aim to improve patient outcomes by reducing the risk of non-hemolytic febrile transfusion reactions and other complications associated with leukocytes in transfused blood components.
The company provides innovative filtration sets that enable real-time processing of whole blood. This allows for more efficient and immediate preparation of blood components for transfusion, potentially enhancing the quality of care for patients requiring blood transfusions.
These specialized filters are designed for the efficient separation of blood components. Their use facilitates the precise extraction of specific blood elements, which is critical for various diagnostic and therapeutic applications.
Targeted at laboratory and clinical settings, the Minipuri filters offer a convenient and effective solution for the rapid screening of cellular components in smaller volumes of blood or other biological fluids, enhancing the speed and accuracy of diagnostic processes.
At the heart of Puriblood's innovation lies the P-Tex Technology, which is distinguished by its bio-inspired molecular formula – a zwitterionic copolymer structure. This technology forms the basis of their advanced filtration products, boasting high efficiency and selectivity in blood component separation while minimizing potential adverse reactions.